Binding of AR to SMRT/N-CoR complex and its co-operation with PSA promoter in prostate cancer cells treated with natural histone deacetylase inhibitor NaB

Neoplasma

Volumn 57, Issue 5, 2010, Pages 406-414

  Trtkova, K ^a   Paskova, L ^a   Matijescukova, N ^a   Strnad, M ^a   Kolar, Z ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Androgen receptor (AR); AR corepressor; Chromatin immunoprecipitation (ChIP); HDAC inhibitor; Histone deacetylases; Sodium butyrate (NaB)

Indexed keywords

ANDROGEN RECEPTOR; BUTYRIC ACID; DNA; HISTONE DEACETYLASE 3; PROSTATE SPECIFIC ANTIGEN; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; TRICHOSTATIN A; ABCC5 PROTEIN, HUMAN; AR PROTEIN, HUMAN; BUTYRIC ACID DERIVATIVE; HDAC2 PROTEIN, HUMAN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; MULTIDRUG RESISTANCE PROTEIN; NCOR1 PROTEIN, HUMAN; RECEPTOR INTERACTING PROTEIN 140;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR BINDING; WESTERN BLOTTING; GENETICS; METABOLISM; PROMOTER REGION; PROSTATE TUMOR; TUMOR CELL LINE;

BUTYRATES; CELL LINE, TUMOR; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NUCLEAR RECEPTOR CO-REPRESSOR 1; PROMOTER REGIONS, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 79952108732     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2010_05_406     Document Type: Article

References (40)

1. HERMANSON O, GLASS CK, ROSENFELD MG. Nuclear receptor coregulators: multiple modes of modification Trends Endocrinol. Metab. 2002; 13: 55-60. doi:10.1016/S1043-2760(01)00527-6
2. AGOULNIK IU, WEIGEL NL. Coactivator selective regulation of androgen receptor activity. Steroids 2009; 74: 669-674. doi:10.1016/j.steroids.2009.02.007
3. CHANG HC, CHEN SC, CHEN J, HSIEH JT. In vitro gene expression changes of androgen receptor coactivators after hormone deprivation in an androgen-dependent prostate cancer cell line. J. Formos. Med. Assoc. 2005; 104: 652-658.
4. CULIG Z, COMUZZI B, STEINER H, BARTSH G, HOBISH A. Expression and function of androgen receptor coactivators in prostate cancer. J. Steroid Biochem. Mol. Biol. 2004; 92: 265-271. doi:10.1016/j.jsbmb.2004.10.003
5. KANG Z, JÄNNE OA, PALVIMO JJ. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol. Endocrinol. 2004; 118: 2633-2648. doi:10.1210/me.2004-0245
6. BLACKWELL L, NORRIS J, SUTO CM, JANZEN WP. The use of diversity profiling to characterize chemical modulators of the histone deacetylases. Life Sci. 2008; 82: 1050-1058. doi:10.1016/j.lfs.2008.03.004
7. XU WS, PARMIGIANI RB, MARKS PA. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 2007; 26: 5541-5552. doi:10.1038/sj.onc.1210620
8. YOON H, CHAN DW, HUANG Z, LI J, FONDELL JD, et al. Purification and functional characterization of the human NCoR complex: the roles of HDAC3, TBL1 and TBLR1. EMBO J. 2003; 22: 1336-1346. doi:10.1093/emboj/cdg120
9. ZHANG J, KALKUM M, CHAIT BT, ROEDER RG. The NCoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. Mol. Cell 2002; 9: 611-623. doi:10.1016/S1097-2765(02)00468-9
10. LI J, WANG J, WANG JIANXIANG, NAWAZ Z, JOHNSON ML, QIN J, et al. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J. 2000; 19: 4342-4350. doi:10.1093/ emboj/19.16.4342
11. MINUCCI S, PELICCI PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006; 6: 38-51. doi:10.1038/nrc1779
12. HUANG EY, ZHANG J, MISKA EA, GUENTHER MG, KOUZARIDES T, et al. Nuclear receptor co-repressor partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes Dev. 2000; 14: 45-54.
13. DOTZLAW H, MOEHREN U, MINK S, CATO ACB, IÑIGUES L, et al. The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol. Endocrinol. 2002; 16: 661-673. doi:10.1210/me.16.4.661
14. JEPSEN K, HERMANSON O, ONAMI TM, GLEIBERMAN AS, LUNYAK V, et al. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 2000; 102: 753-763. doi:10.1016/S0092-8674(00)00064-7
15. MARKS PS, XU WS. Histone deacetylase inhibitors: Potential in cancer therapy. J. Cell. Biochem. 2009; 107: 600-608. doi:10.1002/jcb.22185
16. JOHNSTONE RW, LICHT JD. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell 2002; 4: 13-18. doi:10.1016/S1535-6108(03)00165-X
17. WANG L, LUO HS, XIA H. Sodium butyrate induces human colon carcinoma HT-29 cell apoptosis through a mitochondrial pathway. J. Int. Med. Res. 2009; 37: 803-811.
18. HOSSAIN Z, KURIHARA H, HOSOKAWA M, TAKAHASHI K. Growth inhibition and induction of differentiation and apoptosis mediated by sodium butyrate in Caco-2 cells with algal glycolipids. In Vitro Cell. Dev. Biol. Anim. 2005; 41: 154-159. doi:10.1290/0409058.1
19. KORKMAZ CG, FRØNSDAL K, ZHANG Y, LORENZO PI, SAATCIOGLU F. Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation-rescue of transcriptionally compromised mutants. J. Endocrinol. 2004; 182: 377-389. doi:10.1677/joe.0.1820377
20. ROKHLIN OW, GLOVER RB, GUSEVA NV, TAGHIYEV AF, KOHLGRAF KG, et al. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Mol. Cancer Res. 2006; 4: 113-123. doi:10.1158/1541-7786.MCR-05-0085
21. FRØNSDAL K, SAATCIOGLU F. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells. Prostate 2005; 62: 299-306. doi:10.1002/pros.20140
22. KIM J, PARK H, IM JY, CHOI WS, KIM HS. Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer. Anticancer Res. 2009; 27: 3285-3292.
23. GUI CY, NGO L, XU WS, RICHON VM, MARKS PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF involves changes in promoter-accociated proteins, including HDAC1. Proc. Natl. Acad. Sci. USA 2004; 100: 1241-1246. doi:10.1073/pnas.0307708100
24. VELDSCHOLTE J, BERREVOETS CA, RIS-STALPERS C, KUIPER C, JENSTER GG. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J. Steroid Biochem. Mol. Biol. 1992; 41: 665-669. doi:10.1016/0960-0760(92)90401-4
25. WU H, HSIEH JT, GLEAVE ME, BROWN NM, PATHAK S, et al. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int. J. Cancer 1994; 57: 406-412. doi:10.1002/ijc.2910570319
26. TILLEY WD, WILSON CM, MARCELLI M, MCPHAUL MJ. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res. 1990; 50: 5382-5386.
27. SOBEL RE, SADAR MD. Cell lines used in prostate cancer research: A compendium of old and new lines-part 1. J. Urol. 2005; 173: 342-359. doi:10.1097/01.ju.0000141580.30910.57
28. CLEUTJENS KB, VAN EEKELEN CC, VAN DER KORPUT HA, BRINKMANN AO, TRAPMAN J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J. Biol. Chem. 1996; 271: 6379-6388. doi:10.1074/jbc.271.11.6379
29. HARING M, OFFERMANN S, DANKER T, HORST I, PETERHANSEL C, STAM M. Chromatin immunoprecipitation: optimization, quantitative analysis and data normalization. Plant Methods 2007; 3: 11-27. doi:10.1186/1746-4811-3-11
30. WONG ML, MEDRANO JF. Real-time PCR for mRNA quantitation. Biotechniques 2005; 39: 75-85. doi:10.2144/ 05391RV01
31. TONGBAI R, IDELMAN G, NORDGARD SH, CUI W, JACOBS JL, et al. Transcriptional networks inferred from molecular signatures of breast cancer. Am. J. Pathol. 2008; 172: 495-509. doi:10.2353/ajpath.2008.061079
32. HARTMAN HB, YU J, ALENGHAT T, ISHIZUKA T, LAZAR MA. The histone-binding code of nuclear receptor corepressors matches the substrate specificity of histone deacetylase 3. EMBO Rep. 2005; 6: 445-451. doi:10.1038/ sj.embor.7400391
33. YOON H, CHOI Y, COLE PA, WONG J. Reading and function of a histone code involved in targeting corepressor complexes for repression. Mol. Cell. Biol. 2005; 25: 324-335. doi:10.1128/ MCB.25.1.324-335.2005
34. ROSENFELD MG, LUNYAK VV, GLASS CK. Senzors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 2006; 20: 1405-1428. doi:10.1101/ gad.1424806
35. LEE C, SUTKOWSKI DM, SENSIBAR JA, KELNER D, KIM I, et al. Regulation of proliferation and production of prostatespecific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endokrinology 1995; 136: 796-803. doi:10.1210/en.136.2.796
36. GUENTHER MG, LANE WS, FISHLE W, VERDIN E, LAZAR MA, et al. A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev. 2000; 14: 1048-1057.
37. LIAO G, CHEN LY, ZHANG A, GODAVARTHY A, XIA F, et al. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J. Biol. Chem. 2003; 278: 5052-5061. doi:10.1074/jbc.M206374200
38. YOON H, WONG J. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist-and antagonist-regulated transcription by androgen receptor. Mol. Endocrinol. 2006; 20: 1048-1060. doi:10.1210/me.2005-0324
39. YU J, LI Y, ISHIZUKA T, GUENTHER MG, LAZAR MA. A SANT motif in the SMRT corepressor interprets the histone code and promotes histone deacetylation. EMBO J. 2003; 22: 3403-3410. doi:10.1093/emboj/cdg326
40. WELSBIE DS, XU J, CHEN Y, BORSU L, SCHER HI, et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate resistant prostate cancer. Cancer Res. 2009; 69: 958-966. doi:10.1158/0008-5472. CAN-08-2216